AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Novo Nordisk's Ozempic and Wegovy are among 15 drugs targeted for Medicare price negotiations in 2027. The U.S. aims to cut ...

A psychoeducational intervention for extrapulmonary manifestations of severe asthma was found feasible and rated as ...

“Emphysema makes it hard to breathe air out of your lungs as it affects the tiny air sacs at the end of the airways where ...

“Emphysema is part of a group of lung conditions which comes under the umbrella term chronic obstructive pulmonary disease ...

Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS ... discuss the array of existing and emerging classes of drugs that could benefit those with ACOS and share their ...

and to propose a possible use of these drugs in asthma management. AUC: Area under the curve; COPD: Chronic obstructive pulmonary disease; FEV1: Forced expiratory volume in 1 s; HYP: Hyperosmolar ...